News & Updates

Show Multimedia Only

Functional outcome improvements with atogepant sustained until 3 years

15 Jul 2026 by

A 156-week safety extension study presented at EAN 2026 shows the first 3-year long-term results for atogepant in the preventive treatment of migraine in individuals with chronic migraine (CM) or episodic migraine (EM) who had an insufficient response to 2–4 classes of conventional oral, non-migraine-specific preventive migraine treatments.

Functional outcome improvements with atogepant sustained until 3 years

15 Jul 2026

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

In the treatment of patients with eosinophilic gastritis, the use of dupilumab helps improve histological outcomes, according to the proof-of-concept, phase II DEGAS study.

Dupilumab shows therapeutic potential in eosinophilic gastritis

15 Jul 2026

Contraceptive progestogens carry meningioma risk

14 Jul 2026

Progestogens used for contraception contribute to an increased risk of meningioma, as shown in a nested case-control study.

Contraceptive progestogens carry meningioma risk

14 Jul 2026

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

14 Jul 2026

Daily intake of calcium-enriched permeate (CP) supplement in two doses is comparably effective as taking calcium carbonate (CC) in suppressing bone turnover markers and maintaining bone mineral density (BMD) in postmenopausal women with vitamin D sufficiency, reveals a study, noting that inulin offers no additional advantage.

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

14 Jul 2026

Cagrilintide–semaglutide improves glycaemic control in early-stage diabetes

14 Jul 2026

Treatment with the combination of cagrilintide plus semaglutide is safe and efficacious for lowering glycaemic levels in individuals with early-stage type 2 diabetes inadequately controlled with diet and exercise, as shown in the phase IIIa REIMAGINE 1 trial.

Cagrilintide–semaglutide improves glycaemic control in early-stage diabetes

14 Jul 2026

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

14 Jul 2026 by

Treatment with nipocalimab significantly improves haemoglobin (Hgb) levels as early as week 1, with effects persisting through week 24 in patients with warm autoimmune haemolytic anaemia (wAIHA), according to the phase II/III ENERGY trial presented at EHA 2026.

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

14 Jul 2026

Topical ivermectin, encapsulated benzoyl peroxide come first among rosacea medications

13 Jul 2026 by

Topical ivermectin and encapsulated benzoyl peroxide demonstrate superior short-term efficacy compared with metronidazole in the treatment of adults with moderate-to-severe rosacea in a network meta-analysis, although encapsulated benzoyl peroxide is also associated with higher treatment discontinuation rates due to adverse events.

Topical ivermectin, encapsulated benzoyl peroxide come first among rosacea medications

13 Jul 2026

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

13 Jul 2026

Patients with diabetes mellitus, heart failure, or chronic kidney disease treated with sodium glucose co-transporter-2 inhibitors (SGLT2i) have a reduced risk of mortality from cardiovascular and renal causes, according to a study.

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

13 Jul 2026

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026 by

Treatment with dupilumab for up to 100 weeks reduces the frequency and severity of symptoms in children with eosinophilic esophagitis (EoE), as measured by the validated Pediatric Eosinophilic Esophagitis Symptom Score version 2.0 (PEESSv2.0), according to results from the open-label extension of the phase III EoE KIDS study.

Long-term dupilumab sustains symptom improvement in paediatric EoE

13 Jul 2026

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

13 Jul 2026

The use of leukotriene receptor antagonists (LTRAs), especially when combined with H1 antihistamines (H1AHs), can lower the risk of lung cancer in patients with asthma or allergic rhinitis, suggests a study.

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

13 Jul 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Functional outcome improvements with atogepant sustained until 3 years

Functional outcome improvements with atogepant sustained until 3 years

Dupilumab shows therapeutic potential in eosinophilic gastritis

Dupilumab shows therapeutic potential in eosinophilic gastritis

Contraceptive progestogens carry meningioma risk

Contraceptive progestogens carry meningioma risk

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

Calcium-enriched permeate supplement prevents bone loss in postmenopausal women

Cagrilintide–semaglutide improves glycaemic control in early-stage diabetes

Cagrilintide–semaglutide improves glycaemic control in early-stage diabetes

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

Nipocalimab shows rapid, durable Hgb improvement in adults with wAIHA

Topical ivermectin, encapsulated benzoyl peroxide come first among rosacea medications

Topical ivermectin, encapsulated benzoyl peroxide come first among rosacea medications

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

SGLT2 inhibitor use helps reduce cardiovascular, renal deaths

Long-term dupilumab sustains symptom improvement in paediatric EoE

Long-term dupilumab sustains symptom improvement in paediatric EoE

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases

H1 antihistamine plus LTRA helps prevent lung cancer in patients with allergic diseases